306 related articles for article (PubMed ID: 15580413)
1. How to avoid discontinuation of ribavirin in combination with interferon to maintain efficacy of treatment for chronic hepatitis C patients.
Kasahara A
J Gastroenterol; 2004 Nov; 39(11):1125-6. PubMed ID: 15580413
[No Abstract] [Full Text] [Related]
2. Ribavirin-induced hemolytic anemia in chronic hepatitis C patients.
Itoh Y; Okanoue T
J Gastroenterol; 2004 Jul; 39(7):704-5. PubMed ID: 15293148
[No Abstract] [Full Text] [Related]
3. Tolerability of Peg interferon-alpha2b and Ribavirin therapy in patients with chronic hepatitis C and glucose-6-phosphate dehydrogenase deficiency.
Demelia L; Civolani A; Murgia D; Murru A; Sorbello O; Rizzetto M
J Hepatol; 2007 Jan; 46(1):171-3. PubMed ID: 17107736
[No Abstract] [Full Text] [Related]
4. Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
J Gastroenterol; 2004 Nov; 39(11):1090-4. PubMed ID: 15580403
[TBL] [Abstract][Full Text] [Related]
5. [Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases].
Lopukhova NL
Eksp Klin Gastroenterol; 2007; (4):146-52. PubMed ID: 18409502
[No Abstract] [Full Text] [Related]
6. An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C.
Tinè F; Graviano D; Giannuoli G; Madonia S; Malizia G; Patti S; Fasola S; Cottone M; D'Amico G;
Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1113-23. PubMed ID: 20848397
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of chronic hepatitis C: interferon alpha-2b alone or in combination with ribavirin].
Fontaine H; Pol S
Gastroenterol Clin Biol; 1999 Apr; 23(4):541-4. PubMed ID: 10416124
[No Abstract] [Full Text] [Related]
8. [Ribavirin in combination with interferon alpha-2b in the treatment of chronic hepatitis C].
Hillon P
Presse Med; 2001 Feb; 30(7):335-6. PubMed ID: 11262810
[No Abstract] [Full Text] [Related]
9. Interferon alpha and ribavirin in the treatment of children with chronic hepatitis C.
Figlerowicz M; Sluzewski W; Kowala-Piaskowska A; Mozer-Lisewska I
Eur J Pediatr; 2004 Apr; 163(4-5):265-7. PubMed ID: 14991399
[No Abstract] [Full Text] [Related]
10. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C.
Takaki S; Tsubota A; Hosaka T; Akuta N; Someya T; Kobayashi M; Suzuki F; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Gastroenterol; 2004 Jul; 39(7):668-73. PubMed ID: 15293138
[TBL] [Abstract][Full Text] [Related]
11. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
Sostegni R; Ghisetti V; Pittaluga F; Marchiaro G; Rocca G; Borghesio E; Rizzetto M; Saracco G
Hepatology; 1998 Aug; 28(2):341-6. PubMed ID: 9695995
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune disorders during interferon therapy in a patient with chronic hepatitis C infection: how many of them can be observed in a single patient?
Hrstic I; Huic D; Bilusic M; Vucelic B
J Clin Gastroenterol; 2006 Apr; 40(4):367-8. PubMed ID: 16633111
[No Abstract] [Full Text] [Related]
13. Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C.
Oze T; Hiramatsu N; Kurashige N; Tsuda N; Yakushijin T; Kanto T; Takehara T; Kasahara A; Kato M; Yoshihara H; Katayama K; Kubota S; Hijioka T; Ishibashi K; Oshita M; Hagiwara H; Haruna Y; Mita E; Tamura S; Hayashi N
J Gastroenterol; 2006 Sep; 41(9):862-72. PubMed ID: 17048050
[TBL] [Abstract][Full Text] [Related]
14. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.
González-Peralta RP; Kelly DA; Haber B; Molleston J; Murray KF; Jonas MM; Shelton M; Mieli-Vergani G; Lurie Y; Martin S; Lang T; Baczkowski A; Geffner M; Gupta S; Laughlin M;
Hepatology; 2005 Nov; 42(5):1010-8. PubMed ID: 16250032
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous reactions to interferon and ribavirin.
Chamberlain AJ; Poon E
Intern Med J; 2004 Aug; 34(8):519. PubMed ID: 15317557
[No Abstract] [Full Text] [Related]
16. Factors contributing to ribavirin-induced anemia.
Nomura H; Tanimoto H; Kajiwara E; Shimono J; Maruyama T; Yamashita N; Nagano M; Higashi M; Mukai T; Matsui Y; Hayashi J; Kashiwagi S; Ishibashi H
J Gastroenterol Hepatol; 2004 Nov; 19(11):1312-7. PubMed ID: 15482540
[TBL] [Abstract][Full Text] [Related]
17. Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy.
Brochot E; Castelain S; Duverlie G; Capron D; Nguyen-Khac E; François C
Antivir Ther; 2010; 15(5):687-95. PubMed ID: 20710050
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of combination therapy with pegylated interferon alpha-2a and ribavirin in treating patients with chronic hepatitis C and beta-thalassaemia major: a Greek single-center experience.
Paschos P; Vlachaki E; Pasvanti C; Sinakos E; Kalpaka A; Klonizakis P; Perifanis V
Acta Haematol; 2011; 126(4):231-3. PubMed ID: 21934299
[No Abstract] [Full Text] [Related]
19. Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful?
Balestrieri C; Serra G; Cauli C; Chessa L; Balestrieri A; Farci P
Blood; 2006 Apr; 107(8):3409-10. PubMed ID: 16597599
[No Abstract] [Full Text] [Related]
20. Interferon and ribavirin treatment for chronic hepatitis C may activate celiac disease.
Adinolfi LE; Durante Mangoni E; Andreana A
Am J Gastroenterol; 2001 Feb; 96(2):607-8. PubMed ID: 11232725
[No Abstract] [Full Text] [Related]
[Next] [New Search]
